Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma
Colm Keane, Soi Cheng Law, Clare Gould, et al.
Blood Advances (2020) Vol. 4, Iss. 7, pp. 1367-1377
Open Access | Times Cited: 82

Showing 1-25 of 82 citing articles:

LAG-3: from molecular functions to clinical applications
Takumi Maruhashi, Daisuke Sugiura, Il‐mi Okazaki, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e001014-e001014
Open Access | Times Cited: 360
Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer
An‐Ping Shi, Xiyang Tang, Yanlu Xiong, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 124
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Letong Cai, Yuchen Li, Jiaxiong Tan, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 119
Rethinking immune checkpoint blockade: ‘Beyond the T cell’
Xiuting Liu, Graham D. Hogg, David G. DeNardo
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 1, pp. e001460-e001460
Open Access | Times Cited: 107
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial
Jason J. Luke, Manish R. Patel, George R. Blumenschein, et al.
Nature Medicine (2023) Vol. 29, Iss. 11, pp. 2814-2824
Open Access | Times Cited: 46
The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time’s a Charm
Quentin Lecocq, Marleen Keyaerts, Nick Devoogdt, et al.
International Journal of Molecular Sciences (2020) Vol. 22, Iss. 1, pp. 75-75
Open Access | Times Cited: 115
Targeting immune checkpoints in hematological malignancies
Basit Salik, Mark J. Smyth, Kyohei Nakamura
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 106
Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities
Yingyue Liu, Xiangxiang Zhou, Xin Wang
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 90
Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy
Lawrence P. Andrews, Anthony R. Cillo, Lilit Karapetyan, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 23, pp. 5030-5039
Open Access | Times Cited: 67
Multiplex Tissue Imaging: Spatial Revelations in the Tumor Microenvironment
Stephanie van Dam, Matthijs J.D. Baars, Yvonne Vercoulen
Cancers (2022) Vol. 14, Iss. 13, pp. 3170-3170
Open Access | Times Cited: 47
Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison
Linyan Cheng, Lujun Chen, Yuan Shi, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 8
Gene of the month: lymphocyte-activation gene 3 (LAG-3)
Mark P. Lythgoe, Daniel Liu, Nicola Annels, et al.
Journal of Clinical Pathology (2021) Vol. 74, Iss. 9, pp. 543-547
Closed Access | Times Cited: 43
Immune-Checkpoint Inhibitors in B-Cell Lymphoma
Marc Armengol, Juliana C. Santos, Miranda Fernández-Serrano, et al.
Cancers (2021) Vol. 13, Iss. 2, pp. 214-214
Open Access | Times Cited: 42
Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
Dia Roy, Cassandra Gilmour, Sachin Patnaik, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 21
Novel immune checkpoint targets: A promising therapy for cancer treatments
Mohsina Patwekar, Nouroz Sehar, Faheem Patwekar, et al.
International Immunopharmacology (2023) Vol. 126, pp. 111186-111186
Closed Access | Times Cited: 20
Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy
Salima Shebbo, Najat Binothman, Manar Darwaish, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade
Quentin Lecocq, Robin Maximilian Awad, Yannick De Vlaeminck, et al.
Journal of Nuclear Medicine (2021) Vol. 62, Iss. 11, pp. 1638-1644
Open Access | Times Cited: 33
Modelling the tumor immune microenvironment for precision immunotherapy
Nathan J. Mackenzie, Clarissa Nicholls, Abby R. Templeton, et al.
Clinical & Translational Immunology (2022) Vol. 11, Iss. 6
Open Access | Times Cited: 23
Applicability of Spatial Technology in Cancer Research
Sangjeong Ahn, Hye Seung Lee
Cancer Research and Treatment (2024) Vol. 56, Iss. 2, pp. 343-356
Open Access | Times Cited: 5
Defining Human Regulatory T Cells beyond FOXP3: The Need to Combine Phenotype with Function
Chelsea Gootjes, Jaap Jan Zwaginga, Bart O. Roep, et al.
Cells (2024) Vol. 13, Iss. 11, pp. 941-941
Open Access | Times Cited: 5
Better Outcomes for Ovarian Cancer Associated With the Detection of Anti‐EBV TCR CDR3s: Potential Relevance to Diffuse Large B‐Cell Lymphoma
Nandini Goel, Madeline C. Baker, Michael T. Aboujaoude, et al.
American Journal of Reproductive Immunology (2025) Vol. 93, Iss. 1
Closed Access
Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization
Mengzhou Guo, Qi Feng, Qianwen Rao, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 31
Clinical and research applications of multiplexed immunohistochemistry and in situ hybridization
Lisa McGinnis, Veronica Ibarra‐Lopez, Sandra Rost, et al.
The Journal of Pathology (2021) Vol. 254, Iss. 4, pp. 405-417
Open Access | Times Cited: 29
Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples
Qiang Liu, Yihang Qi, Jie Zhai, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 28
Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies
Kamira Maharaj, Angimar Uriepero, Eva Sahakian, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top